Terms: = Breast cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791
13 results:
1. CED: A case-level explainable paramedical diagnosis via AdaGBDT.
Guo Z; Xu M; Yang Y; Li Y; Wu H; Zhu Z; Zhao Y
Comput Biol Med; 2023 Feb; 153():106500. PubMed ID: 36592608
[TBL] [Abstract] [Full Text] [Related]
2. Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3
Zhou Q; Lin W; Wang C; Sun F; Ju S; Chen Q; Wang Y; Chen Y; Li H; Wang L; Hu Z; Jin H; Wang X; Sun Y
Nat Commun; 2022 May; 13(1):3034. PubMed ID: 35641493
[TBL] [Abstract] [Full Text] [Related]
3. Prostate cancer-associated spop mutations lead to genomic instability through disruption of the spop-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract] [Full Text] [Related]
4. The GPER1/spop axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract] [Full Text] [Related]
5. Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer.
Meng F; Su Y; Xu B
Mol Oncol; 2020 Nov; 14(11):2701-2712. PubMed ID: 32941674
[TBL] [Abstract] [Full Text] [Related]
6. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract] [Full Text] [Related]
7. cancer Mutations of the Tumor Suppressor spop Disrupt the Formation of Active, Phase-Separated Compartments.
Bouchard JJ; Otero JH; Scott DC; Szulc E; Martin EW; Sabri N; Granata D; Marzahn MR; Lindorff-Larsen K; Salvatella X; Schulman BA; Mittag T
Mol Cell; 2018 Oct; 72(1):19-36.e8. PubMed ID: 30244836
[TBL] [Abstract] [Full Text] [Related]
8. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing spop-mediated c-Myc degradation in triple-negative breast cancer.
Luo L; Tang H; Ling L; Li N; Jia X; Zhang Z; Wang X; Shi L; Yin J; Qiu N; Liu H; Song Y; Luo K; Li H; He Z; Zheng G; Xie X
Oncogene; 2018 Nov; 37(47):6166-6179. PubMed ID: 30002443
[TBL] [Abstract] [Full Text] [Related]
9. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract] [Full Text] [Related]
10. Relationship between spop mutation and breast cancer in Chinese population.
Khan MA; Zhu L; Tania M; Xiao XL; Fu JJ
Genet Mol Res; 2015 Oct; 14(4):12362-6. PubMed ID: 26505385
[TBL] [Abstract] [Full Text] [Related]
11. Prostate cancer-associated mutations in speckle-type POZ protein (spop) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract] [Full Text] [Related]
12. breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-spop E3 ubiquitin ligase complex.
Kim B; Nam HJ; Pyo KE; Jang MJ; Kim IS; Kim D; Boo K; Lee SH; Yoon JB; Baek SH; Kim JH
Biochem Biophys Res Commun; 2011 Dec; 415(4):720-6. PubMed ID: 22085717
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-suppressor role for the spop ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.
Li C; Ao J; Fu J; Lee DF; Xu J; Lonard D; O'Malley BW
Oncogene; 2011 Oct; 30(42):4350-64. PubMed ID: 21577200
[TBL] [Abstract] [Full Text] [Related]
